The fresco of autoinflammatory diseases from the pediatric perspective

Autoimmunity Reviews

Volumn 11, Issue 5, 2012, Pages 348-356

  Rigante, Donato ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Autoinflammatory disease; Interleukin 1; Pediatrics

Indexed keywords

INTERLEUKIN 1; MEVALONATE KINASE;

ANGIONEUROTIC EDEMA; AUTOINFLAMMATORY DISEASE; BEHCET DISEASE; BLAU SYNDROME; CINCA SYNDROME; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL MEDITERRANEAN FEVER; HEMOLYTIC UREMIC SYNDROME; HUMAN; MAJEED SYNDROME; MEVALONATE KINASE DEFICIENCY; MUCKLE WELLS SYNDROME; PAPA SYNDROME; PATHOGENESIS; PEDIATRICS; REVIEW; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

BEHCET SYNDROME; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; FAMILIAL MEDITERRANEAN FEVER; GRANULOMATOUS DISEASE, CHRONIC; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; MEVALONATE KINASE DEFICIENCY;

EID: 84857500409     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.10.008     Document Type: Review

References (78)

1. Goldfinger S. The inherited autoinflammatory syndrome: a decade of discovery. Trans Am Clin Climatol Assoc 2009, 120:413-418.
2. Rigante D., Capoluongo E. The plodding diagnosis of monogenic autoinflammatory diseases in childhood. Clin Chem Lab Med 2011, 49:783-791.
3. Rodrigue-Gervais I.G., Saleh M. Genetics of inflammasome-associated disorders: a lesson in the guiding principals of inflammasome function. Eur J Immunol 2010, 40:643-648.
4. Henderson C., Goldbach-Mansky R. Monogenic autoinflammatory diseases: new insights into clinical aspects and pathogenesis. Curr Opin Rheumatol 2010, 22:567-578.
5. Aksentijevich I., D Putnam C., Remmers E.F., Mueller J.L., Le J., Kolodner R.D., et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007, 56:1273-1285.
6. Maksimovic L., Stirnemann J., Caux F., Ravet N., Rouaghe S., Cuisset L., et al. New CIAS1 mutation and anakinra efficacy in overlapping of Muckle-Wells and familial cold autoinflammatory syndromes. Rheumatology (Oxford) 2008, 47:309-310.
7. Prieur A.M. A recently recognised chronic inflammatory disease of early onset characterised by the triad of rash, central nervous system involvement and arthropathy. Clin Exp Rheumatol 2001, 19:103-106.
8. Bilginer Y., Akpolat T., Ozen S. Renal amyloidosis in children. Pediatr Nephrol 2011, 26:1215-1227.
9. Yu J.R., Leslie K.S. Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response. Curr Allergy Asthma Rep 2011, 11:12-20.
10. Neven B., Marvillet I., Terrada C., Ferster A., Boddaert N., Couloignier V., et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 2010, 62:258-267.
11. Goldbach-Mansky R., Shroff S.D., Wilson M., Snyder C., Plehn S., Barham B., et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 2008, 58:2432-2442.
12. Lachmann H.J., Kone-Paut I., Kuemmerle-Deschner J.B., Leslie K.S., Hachulla E., Quartier P., et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009, 360:2416-2425.
13. Tinazzi E., Puccetti A., Patuzzo G., Sorleto M., Barbieri A., Lunardi C. Schnitzler syndrome, an autoimmune-autoinflammatory syndrome: report of two new cases and review of the literature. Autoimmun Rev 2011, 10:404-409.
14. Jéru I., Duquesnoy P., Fernandes-Alnemri T., Cochet E., Yu J.W., Lackmy-Port-Lis M., et al. Mutations in NALP12 cause hereditary periodic fever syndromes. Proc Natl Acad Sci U S A 2008, 105:1614-1619.
15. Guz G., Kanbay M., Ozturk M.A. Current perspectives on familial Mediterranean fever. Curr Opin Infect Dis 2009, 22:309-315.
16. Ben-Chetrit E., Touitou I. Familial Mediterranean fever in the world. Arthritis Rheum 2009, 61:1447-1453.
17. Sohar E., Gafni J., Pras M., Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 1967, 43:227-253.
18. Lachmann H.J., Sengul B., Yavuzşen T.U., Booth D.R., Booth S.E., Bybee A., et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 2006, 45:746-750.
19. Samuels J., Aksentijevich I., Torosyan Y., Centola M., Deng Z., Sood R., et al. Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine (Baltimore) 1998, 77:268-297.
20. Touitou I., Sarkisian T., Medlej-Hashim M., Tunca M., Livneh A., Cattan D., et al. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 2007, 56:1706-1712.
21. Soylemezoglu O., Arga M., Fidan K., Gonen S., Emeksiz H.C., Hasanoglu E., et al. Unresponsiveness to colchicine therapy in patients with familial Mediterranean fever homozygous for the M694V mutation. J Rheumatol 2010, 37:182-189.
22. Marek-Yagel D., Berkun Y., Padeh S., Abu A., Reznik-Wolf H., Livneh A., et al. Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum 2009, 60:1862-1866.
23. Livneh A., Langevitz P., Zemer D., Zaks N., Kees S., Lidar T., et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997, 40:1879-1885.
24. Yalçinkaya F., Ozen S., Ozçakar Z.B., Aktay N., Çakar N., Düzova A., et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford) 2009, 48:395-398.
25. Rigante D., La Torraca I., Avallone L., Pugliese A.L., Gaspari S., Stabile A. The pharmacological basis of treatment with colchicine in children with familial Mediterranean fever. Eur Rev Med Pharmacol Sci 2006, 10:173-178.
26. Roldan R., Ruiz A.M., Miranda M.D., Collantes E. Anakinra: new therapeutic approach in children with familial Mediterranean fever resistant to colchicine. Joint Bone Spine 2008, 75:504-505.
27. van der Meer J.W., Vossen J.M., Radl J., van Nieuwkoop J.A., Meyer C.J., Lobatto S., et al. Hyperimmunoglobulinaemia D and periodic fever: a new syndrome. Lancet 1984, 1(8386):1087-1090.
28. Frenkel J., Houten S.M., Waterham H.R., Wanders R.J.A., Rijkers G.T., Kimpen J.L.L., et al. Mevalonate kinase deficiency and Dutch type periodic fever. Clin Exp Rheumatol 2000, 18:525-532.
29. Drenth J.P., van Deuren M., van der Ven-Jongekrijg J., Schalkwijk C.G., van der Meer J.W. Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Blood 1995, 85:3586-3593.
30. van der Hilst J.C., Bodar E.J., Barron K.S., Frenkel J., Drenth J.P., van der Meer J.W., et al. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) 2008, 87:301-310.
31. Simon A., Kremer H.P., Wevers R.A., Scheffer H., De Jong J.G., van der Meer J.W., et al. Mevalonate kinase deficiency: evidence for a phenotypic continuum. Neurology 2004, 62:994-997.
32. Siewert R., Ferber J., Horstmann R.D., Specker C., Heering P.J., Timmann C. Hereditary periodic fever with systemic amyloidosis: is hyper-IgD syndrome really a benign disease?. Am J Kidney Dis 2006, 48:e41-e45.
33. Drenth J.P., Haagsma C.J., van der Meer J.W. Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Baltimore) 1994, 73:133-144.
34. Ammouri W., Cuisset L., Rouaghe S., Rolland M.O., Delpech M., Grateau G., et al. Diagnostic value of serum immunoglobulinaemia D level in patients with a clinical suspicion of hyper IgD syndrome. Rheumatology (Oxford) 2007, 46:1597-1600.
35. Takada K., Aksentijevich I., Mahadevan V., Dean J.A., Kelley R.I., Kastner D.L. Favorable preliminary experience with etanercept in two patients with the hyperimunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2003, 48:2645-2651.
36. Rigante D., Ansuini V., Bertoni B., Pugliese A.L., Avallone L., Federico G., et al. Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome. Rheumatol Int 2006, 27:97-100.
37. Bodar E.J., van der Hilst J.C., Drenth J.P., van der Meer J.W., Simon A. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth J Med 2005, 63:260-264.
38. Mancini J., Philip N., Chabrol B., Divry P., Rolland M.O., Pinsard N. Mevalonic aciduria in 3 siblings: a new recognizable metabolic encephalopathy. Pediatr Neurol 1993, 9:243-246.
39. Mandey S.H.L., Schneiders M.S., Koster J., Waterham H.R. Mutational spectrum and genotype-phenotype correlations in mevalonate kinase deficiency. Hum Mutat 2006, 27:796-802.
40. Williamson L.M., Hull D., Mehta R., Reeves W.G., Robinson B.H., Toghill P.J. Familial Hibernian fever. Q J Med 1982, 51:469-480.
41. Aksentijevich I., Galon J., Soares M., Mansfield E., Hull K., OH H.H., et al. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 2001, 69:301-314.
42. Nedjai B., Hitman G.A., Church L.D., Minden K., Whiteford M.L., McKee S., et al. Differential cytokine secretion results from p65 and c-Rel NF-κB subunit signaling in peripheral blood mononuclear cells of TNF receptor-associated periodic syndrome patients. Cell Immunol 2011, 268:55-59.
43. Stojanov S., McDermott M.F. The tumour necrosis factor receptor-associated periodic syndrome: current concepts. Expert Rev Mol Med 2005, 7:1-18.
44. Dinc A., Erdem H., Rowczenio D., Simsek I., Pay S., Bahce M., et al. Autosomal dominant periodic fever with AA amyloidosis: tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a Turkish family. J Nephrol 2005, 18:626-629.
45. Cantarini L., Rigante D., Lucherini O.M., Cimaz R., Laghi Pasini F., Baldari C.T., et al. Role of etanercept in the treatment of tumor necrosis factor receptor-associated periodic syndrome: personal experience and review of the literature. Int J Immunopathol Pharmacol 2010, 23:701-707.
46. Gattorno M., Pelagatti M.A., Meini A., Obici L., Barcellona R., Federici S., et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008, 58:1516-1520.
47. Tallon B., Corkill M. Peculiarities of PAPA syndrome. Rheumatology (Oxford) 2006, 45:1140-1143.
48. Stichweh D.S., Punaro M., Pascual V. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. Pediatr Dermatol 2005, 22:262-265.
49. Ferguson P.J., Chen S., Tayeh M.K., Ochoa L., Leal S.M., Pelet A., et al. Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome). J Med Genet 2005, 42:551-557.
50. Aksentijevich I., Masters S.L., Ferguson P.J., Dancey P., Frenkel J., van Royen-Kerkhoff A., et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009, 360:2426-2437.
51. Ferguson P.J., El-Shanti H.I. Autoinflammatory bone disorders. Curr Opin Rheumatol 2007, 19:492-498.
52. Blau E.B. Familial granulomatous arthritis, iritis, and rash. J Pediatr 1985, 107:689-693.
53. Kanazawa N., Okafuji I., Kambe N., Nishikomori R., Nakata-Hizume M., Nagai S., et al. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. Blood 2005, 105:1195-1197.
54. Rosé C.D., Wouters C.H., Meiorin S., Doyle T.M., Davey M.P., Rosenbaum J.T., et al. Pediatric granulomatous arthritis: an international registry. Arthritis Rheum 2006, 54:3337-3344.
55. Fink C.W., Cimaz R. Early onset sarcoidosis: not a benign disease. J Rheumatol 1997, 24:174-177.
56. Petty R.E., Southwood T.R., Manners P., Baum J., Glass D.N., Goldenberg J., et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004, 31:390-392.
57. Prieur A.M., Chèdeville G. Prognostic factors in juvenile idiopathic arthritis. Curr Rheumatol Rep 2001, 3:371-378.
58. Yeh T.L., Huang F.Y., Shyur S.D., Chen T.L., Lee C.S., Huang D.T. Juvenile idiopathic arthritis presenting with prolonged fever. J Microbiol Immunol Infect 2010, 43:169-174.
59. Quartier P. Current treatments for juvenile idiopathic arthritis. Joint Bone Spine 2010, 77:511-516.
60. Lee W.I., Yang M.H., Lee K.F., Chen L.C., Lin S.J., Yeh K.W., et al. PFAPA syndrome (Periodic Fever, Aphthous stomatitis, Pharyngitis, Adenitis). Clin Rheumatol 1999, 18:207-213.
61. Tasher D., Somekh E., Dalal I. PFAPA syndrome: new clinical aspects disclosed. Arch Dis Child 2006, 91:981-984.
62. Feder H.M., Salazar J.C. A clinical review of 105 patients with PFAPA (a periodic fever syndrome). Acta Paediatr 2010, 99:178-184.
63. Stojanov S., Lapidus S., Chitkara P., Feder H., Salazar J.C., Fleisher T.A., et al. Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade. Proc Natl Acad Sci U S A 2011, 108:7148-7153.
64. Nussberger J., Cugno M., Amstutz C., Cicardi M., Pellacani A., Agostoni A. Plasma bradykinin in angio-oedema. Lancet 1998, 351:1693-1697.
65. Lipsker D., Hauptmann G. Cutaneous manifestations of complement deficiencies. Lupus 2010, 19:1096-1106.
66. Gompels M.M., Lock R.J. C1 inhibitor deficiency: management. Clin Exp Dermatol 2005, 30:737-740. Advisory Group.
67. Christiansen S.C., Zuraw B.L. Update on therapeutic developments for hereditary angioedema. Allergy Asthma Proc 2009, 30:500-505.
68. Bouillet L. Icatibant in hereditary angioedema: news and challenges. Expert Rev Clin Immunol 2011, 7:267-272.
69. Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009, 361:1676-1687.
70. Le Quintrec M., Roumenina L., Noris M., Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes. Semin Thromb Hemost 2010, 36:641-652.
71. de Jorge E.G., Macor P., Paixão-Cavalcante D., Rose K.L., Tedesco F., Cook H.T., et al. The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol 2011, 22:137-145.
72. Rosales A., Riedl M., Zimmerhackl L.B. Thrombotic microangiopathy: atypical HUS: current diagnostic and therapeutic approaches. Nat Rev Nephrol 2010, 6:504-506.
73. Roumenina L.T., Loirat C., Dragon-Durey M.A., Halbwachs-Mecarelli L., Sautes-Fridman C., Fremeaux-Bacchi V. Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods 2011, 365:8-26.
74. Taylor C.M., Machin S., Wigmore S.J., Goodship T.H. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol 2010, 148:37-47. Working Party from the Renal Association, the British Committee for Standards in Haematology and the British Transplantation Society.
75. Châtelet V., Lobbedez T., Frémeaux-Bacchi V., Ficheux M., Ryckelynck J.P., Hurault de Ligny B. Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Transplant Proc 2010, 42:4353-4355.
76. Direskeneli H. Autoimmunity vs autoinflammation in Behcet's disease: do we oversimplify a complex disorder?. Rheumatology (Oxford) 2006, 45:1461-1465.
77. Piga M., Mathieu A. Genetic susceptibility to Behcet's disease: role of genes belonging to the MHC region. Rheumatology (Oxford) 2011, 50:299-310.
78. Kaneko F., Togashi A., Saito S., Sakuma H., Oyama N., Nakamura K., et al. Behçet's disease (Adamantiades-Behçet's disease). Clin Dev Immunol 2011, 681956.